S. Stacchiotti reports from ASCO 2019 on study results presented in soft tissue sarcomas (STS). She explains the heterogeneity of STS and illustrates, using the example of olaratumab, why large trials sometimes don't confirm the promising results obtained in smaller studies in specific subtypes. She also reports on positive results with an EZH2 inhibitor in epithelioid sarcoma.
She explains the heterogeneity of STS and illustrates, using the example of olaratumab, why large trials sometimes don't confirm the promising results obtained in smaller studies in specific subtypes. She also reports on positive results with an EZH2 inhibitor in epithelioid sarcoma.